MASHINIi

Climb Bio, Inc..

CLYM.US | Research and experimental development on natural sciences and engineering

Climb Bio, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of cancer and other serious diseases. The company's pipeline includes a range of preclinical and clinical-stage programs targeting various cancer types. Climb Bio utilizes prop...Show More

Ethical Profile

Mixed.

Climb Bio, Inc. (CLYM.US) shows a mixed ethical profile. Its core mission to develop therapies for immune-mediated diseases like lupus and IgAN, with products like budoprutug and CLYM116, supports better health. Yet, critics point to potential tensions between drug accessibility and profitability. For workers, the CEO's compensation was $6.34M, but reports suggest Climb Bio relies 100% on freelance staff, affecting traditional benefits. As a clinical-stage biotech, its drug development is highly likely to involve animal testing, a practice often seen as fundamentally conflicting with animal welfare. Many areas, including fair trade and environmental impact, lack sufficient public data.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect-50
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess Climb Bio, Inc. on Better Health for All.

Fair Money & Economic Opportunity

0

No evidence available to assess Climb Bio, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

-50

Climb Bio, Inc. has 100% of its workforce on freelance contracts and 0% full-time employees, indicating a highly precarious employment structure.

1
While the company offers benefits such as dental, vision, short/long-term disability, life insurance, 401k match, paid time off, holiday pay, and stock options, it is unclear how these apply to the entire freelance workforce.
2
A separation agreement for a Chief Operating Officer in May 2025 included a severance payment of $128,749.99 and three months of health insurance continuation.
3

Fair Trade & Ethical Sourcing

0

No specific, concrete evidence was found in the provided articles regarding Climb Bio, Inc.'s performance on fair trade and ethical sourcing KPIs. The articles, which include financial reports and an internal code of conduct, do not contain data on supplier certifications, audit frequencies, forced/child labor incidents, supply chain traceability, remediation speed, ethical clauses in supplier contracts, high-risk material spend, or supplier diversity.

1

Honest & Fair Business

0

No specific data related to the 'Honest & Fair Business' ethical value, such as regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification, was provided in the available article.

1

Kind to Animals

0

No evidence available to assess Climb Bio, Inc. on Kind to Animals.

No War, No Weapons

0

No evidence available to assess Climb Bio, Inc. on No War, No Weapons.

Planet-Friendly Business

0

The provided article, a PitchBook profile, focuses on financial and general company information for Climb Bio, Inc. It explicitly states that "No ESG metrics related to Planet-Friendly Business are provided in the profile."

1
Consequently, there is no specific, concrete data available to assess the company against any of the Planet-Friendly Business KPIs, leading to the omission of all KPIs from the scoring. **Explanation of Data Gaps:** The provided PitchBook profile is primarily focused on financial and company background information for Climb Bio (CLYM.US). Crucially, there is no information about the company's environmental, social, and governance (ESG) performance, including any data relevant to planet-friendly business practices.
2
The ESG risk rating is mentioned, but no details are given about the specific metrics that contributed to that rating.
3
Therefore, no data can be extracted for the requested ESG metrics.

Respect for Cultures & Communities

0

No specific, concrete data points were found in the provided articles that directly address the defined KPIs for "Respect for Cultures & Communities" for Climb Bio, Inc. (CLYM.US). The articles primarily contain financial reporting, information about other entities named 'Clym' (such as Lions Services, Clym Environmental Services, or clym.io), or general community planning efforts by a city, none of which provide direct evidence for CLYM.US's performance against these specific ethical metrics.

Safe & Smart Tech

0

No evidence available to assess Climb Bio, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No specific, concrete data points were found in the provided articles regarding Climb Bio, Inc.'s performance on waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.

1

Own Climb Bio, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.